Desloratadine: A new, nonsedating. oral antihistamine

被引:140
作者
Geha, RS
Meltzer, EO
机构
[1] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Boston Childrens Hosp, Boston, MA USA
关键词
desloratadine; antihistamine; seasonal allergic rhinitis; asthma; urticaria; anti-inflammatory; drug interactions; safety; congestion;
D O I
10.1067/mai.2001.114239
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Desloratadine is a new, selective, H-1-receptor antagonist that also has anti-inflammatory activity. In vitro studies have shown that desloratadine inhibits the release or generation of multiple inflammatory mediators, including IL-4, IL-6, IL-8, IL-13, PGD(2), leukotriene C-4, tryptase, histamine, and the TNF-alpha -induced chemokine RANTES, Desloratadine also inhibits the induction of cell adhesion molecules, platelet-activating factor-induced eosinophil chemotaxis, TNF-alpha -induced eosinophil adhesion, and spontaneous and phorbol myristate acetate-induced superoxide generation in vitro. In animals desloratadine had no effect on the central nervous, cardiovascular. renal, or gastrointestinal systems. Desloratadine is rapidly absorbed, has dose-proportional pharmacokinetics, and has a half-life of 27 hours, The absorption of desloratadine is not affected by food, and the metabolism and elimination are not significantly affected by the subject's age, race, or sex, There are no clinically relevant interactions between desloratadine and erythromycin, ketoconazole, or grapefruit juice. Desloratadine is not a significant substrate of the P-glycoprotein transport system, Once daily administration of desloratadine rapidly reduces the nasal and nonnasal symptoms of seasonal allergic rhinitis, including congestion. In patients with seasonal allergic rhinitis and concomitant asthma, desloratadine treatment was also associated with significant reductions in total asthma symptom score and use of inhaled Pz-agonists, Use of desloratadine in patients with chronic idiopathic urticaria was associated with significant reductions in pruritus, number of hives, size of the largest hive, and interference with sleep and daily activities. Clinical experience in over 2300 patients has shown that the adverse event profile of desloratadine is similar to that of placebo; desloratadine has no clinically relevant effects on electrocardiographic parameters, does not impair wakefulness or psychomotor performance, and does not exacerbate the psychomotor impairment associated with alcohol use.
引用
收藏
页码:752 / 762
页数:11
相关论文
共 38 条
[1]  
AFFRIME M, IN PRESS CLIN PHARMA
[2]  
Aguawal DK, 2000, ALLERGY S, V55, P276
[3]  
ANTHES JC, 2000, ALLERGY, V55, P277
[4]  
BANFIELD C, IN PRESS CLIN PHARMA
[5]  
BANFIELD C, 2000, ANN ALLERG ASTHMA IM, V86, P108
[6]   EVALUATION OF THE CNS PROPERTIES OF SCH-29851, A POTENTIAL NON-SEDATING ANTIHISTAMINE [J].
BARNETT, A ;
IORIO, LC ;
KREUTNER, W ;
TOZZI, S ;
AHN, HS ;
GULBENKIAN, A .
AGENTS AND ACTIONS, 1984, 14 (5-6) :590-597
[7]   Pharmacotherapy to prevent the complications of allergic rhinitis [J].
Beckman, DB ;
Grammer, LC .
ALLERGY AND ASTHMA PROCEEDINGS, 1999, 20 (04) :215-223
[8]  
CAYEN M, 2000, ALLERGY S, V55, P282
[9]  
Cvetkovic M, 1999, DRUG METAB DISPOS, V27, P866
[10]   Second-generation antihistamines: The risk of ventricular arrhythmias [J].
DuBuske, LM .
CLINICAL THERAPEUTICS, 1999, 21 (02) :281-295